Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.Learn More
Brentuximab is a type of immunotherapy called a monoclonal antibody. This medicine works by targeting a protein called CD30 found on some types of lymphoma cells. Brentuximab is considered a type of immunotherapy because it uses the patient’s immune system to attack the cancer cells. It is also a targeted therapy because the medicine is specific to certain cell features and “targets” those cells.
Blood pressure, heart rate, breathing, and temperature will be checked regularly during and after the infusion to watch for infusion-related side effects.
Patients will have regular blood draws to check blood counts and monitor kidney and liver function.
Given as a liquid into a vein by IV
Infusion-related reactions: Symptoms may include chills, shortness of breath, coughing, dizziness, low blood pressure, pain in the chest, swelling of the face or neck
Not all patients who take brentuximab will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Be sure to discuss these and other recommendations with your doctor or pharmacist.